A Phase IB, Open-label Pilot Study Designed to Evaluate the Efficacy and Safety of BL-8040 followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects with Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if BL-8040 in combination with hATG, cyclosporine, and methylprednisolone can help to control aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS). The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 02/02/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: